Skip to main navigation Skip to search Skip to main content

The incidence of anosmia in patients with laboratory-confirmed COVID 19 infection in India: An observational study

  • Vinod Kumar
  • , Sapna Singla
  • , Nishkarsh Gupta
  • , Sachidanand Jee Bharati
  • , Rakesh Garg
  • , Anuja Pandit
  • , Saurabh Vig
  • , Seema Mishra
  • , Sushma Bhatnagar

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: Acute loss of smell or anosmia is a common and sometimes the only symptom observed in patients with coronavirus disease-2019 (COVID-19). The objective of the study was to determine the prevalence, time of onset, and duration of anosmia in patients with COVID-19 infection and the association of anosmia with other symptoms and eosinophil count. Material and Methods: Two hundred patients with laboratory-confirmed COVID-19 infection, who were asymptomatic or mildly symptomatic were assessed for olfaction with a nonirritant odor. The presence of anosmia was recorded, and a questionnaire integrating the anosmia reporting tool was filled. Patients with anosmia/hyposmia were followed telephonically at 7 and 14 days for resolution of anosmia and other symptoms. The presence of anosmia was correlated with eosinophil count. Results: Of the 200 COVID-19 patients, 87% were symptomatic. More than half of the patients had fever (56%). Anosmia was observed in 30% of the patients and hyposmia in 4% of patients. In 41% of the patients, olfactory loss was reported before diagnosis. The mean duration of anosmia was 7.8 (± 5) days; 97% of patients recovered with a resolution of symptoms within 2 weeks. Ageusia was the most commonly and significantly associated symptom with anosmia (66%, n = 45) followed by sore throat (41%), and rhinorrhea (28%). The symptoms in both the sexes were comparable. Absolute eosinophil count of <40/μL was observed in 59 patients (29.5%) and an absolute eosinophil count of 0 in 17 patients (8.5%). Among the 68 anosmic patients, 36 (47%) patients had eosinopenia, which was statistically significant. Conclusion: Anosmia is an early and sometimes the only symptom in approximately one-third of the patients with COVID-19 infection. Eosinophil count should be checked in anosomic patient with suspicion of COVID-19 infection. Objective tools for olfactory and gustatory assessment should be brought into practice for early and prompt diagnosis to control the spread of the disease.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalJournal of Anaesthesiology Clinical Pharmacology
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Journal of Anaesthesiology Clinical Pharmacology Published by Wolters Kluwer-Medknow.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Ageusia
  • COVID-19
  • anosmia
  • anosmia reporting tool
  • eosinophil count

Fingerprint

Dive into the research topics of 'The incidence of anosmia in patients with laboratory-confirmed COVID 19 infection in India: An observational study'. Together they form a unique fingerprint.

Cite this